Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

114.74 -5.19 (-4.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,712,266
Open 120.00
Bid (Size) 110.00 (1)
Ask (Size) 117.77 (1)
Prev. Close 119.93
Today's Range 110.56 - 117.60
52wk Range 100.15 - 159.84
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
-8.09%
-8.09%
1 Month
-3.58%
-3.58%
3 Month
+5.97%
+5.97%
6 Month
-12.51%
-12.51%
1 Year
+8.09%
+8.09%

More News

Read More
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
Via The Motley Fool
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Earnings Preview: Sarepta Therapeutics
Via Benzinga
2 Biotech Growth Stocks I'd Buy Right Now
Via The Motley Fool
2 Top Growth Stocks to Buy With $500
Via The Motley Fool
Insiders Are Buying These 2 Stocks
Via MarketBeat
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Where Sarepta Therapeutics Stands With Analysts
Via Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Via The Motley Fool
Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
$3M Bet On Tidewater? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript
Via The Motley Fool
Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
3 Biotech Stocks to Sell Before They Damage Your Portfolio
Via InvestorPlace
Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.